FDMT
NASDAQ · Biotechnology
4D Molecular Therapeutics In
$10.14
+0.21 (+2.11%)
Open$9.08
Previous Close$9.93
Day High$10.16
Day Low$9.06
52W High$12.34
52W Low$3.00
Volume—
Avg Volume650.9K
Market Cap519.09M
P/E Ratio—
EPS$-2.55
SectorBiotechnology
Analyst Ratings
Strong Buy
17 analysts
Price Target
+108.2% upside
Current
$10.14
$10.14
Target
$21.11
$21.11
$12.84
$21.11 avg
$26.25
Key Financials
| FY 2026 | FY 2025 | FY 2024 | |
|---|---|---|---|
| Revenue | 84.00M | 286.9K | 228.58M |
| Net Income | -138,115,132 | -1,099,890,361 | -57,732,834 |
| Profit Margin | -164.4% | -413,039.5% | -25.3% |
| EBITDA | -152,682,720 | -1,322,641,633 | -107,016,126 |
| Free Cash Flow | — | — | -89,291,698 |
| Rev Growth | +200.8% | -87.3% | +10.3% |
| Debt/Equity | — | — | 0.12 |
Biotechnology Peers
| Symbol | Name | Price | Change | P/E | Mkt Cap |
|---|---|---|---|---|---|
| ABBV | Abbvie Inc | $201.55 | -0.57% | 88.1 | 372.29B |
| AMGN | Amgen Inc | $331.70 | +0.79% | 22.7 | 176.88B |
| GILD | Gilead Sciences Inc | $131.33 | -2.04% | 19.3 | 163.92B |
| VRTX | Vertex Pharmaceuticals Inc | $429.82 | +1.13% | 27.7 | 109.50B |
| REGN | Regeneron Pharmaceuticals | $714.89 | +0.82% | 16.5 | 74.30B |
| ALNY | Alnylam Pharmaceuticals Inc | $295.05 | -0.29% | 130.4 | 40.90B |